Systemic lupus erythematosus (SLE) is a complex and heterogeneous condition that is challenging to treat.
In SLE clinical trials, multiple organ involvement is assessed by composite scores, complicating the choice of patient population, drug mechanism, and identifying the appropriate clinical endpoint that will result in a significant signal. Luckily, quantitative systems pharmacology (QSP) can help provide a holistic view of the mechanistic understanding of SLE.
Our SLE QSP model can be used to explore different trial designs, patient subgroups, and a variety of dose-schedule strategies. It can simulate studies based on your inputs and predict likely outcomes, allowing you to narrow your SLE research to the most promising therapies and dosing strategies. It can help you …
And because your research is entirely virtual, you have the flexibility to experiment risk-free with a wide range of inputs and expand understanding of how your compound performs in a variety of scenarios.
Optimize your clinical trial design. Learn more about how our QSP model can support the development of your SLE treatment.
Maria Munoz-Lopez
Francisco Huizar
Noah Brostoff
